16 September 2026 note archive · Item
Kriya muscle-directed AAV gene therapy (VV-14299 / VV-14300; KRIYA.288): review notes
These archived notes document the scope reviewed on 16 September, including source-access limits. They do not cover later changes or newly added records. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: corrected/updated. Current item
lastReviewed: 2026-09-16. - Claim check: Rewritten around current KRIYA.288 glucokinase payload. Identity with historical KRIYA-839 insulin-plus-glucokinase is not established. The sponsor's Phase 1/2 label lacks a located public T1D registration; a sponsor query found four non-T1D studies. Removed unverified PROGRESS eligibility and start promises.
- Primary publication/regulatory sources checked or consulted: PMID 23378612.
- Programme/sponsor/conference source boundary: KRIYA.288 Type 1 Diabetes — current programme specifications (manufacturer).
- Retrieval limit (not a falsity finding): https://doi.org/10.2337/db23-855-P.